CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 30, 2015
Result type: Reports
Project Number: SR0471-000
Product Line: Reimbursement Review

Generic Name: lumacaftor/ivacaftor

Brand Name: Orkambi

Manufacturer: Vertex Pharmaceuticals (Canada) Incorporated.

Therapeutic Area: Cystic Fibrosis, F508del CFTR mutation

Indications: Cystic Fibrosis, F508del CFTR mutation

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 26, 2016

Recommendation Type: Do not reimburse